Akebia Therapeutics (AKBA) Other financing activities (2013 - 2025)

Akebia Therapeutics (AKBA) has 5 years of Other financing activities data on file, last reported at $63000.0 in Q1 2025.

• Other financing activities for Q1 2025 came in at $63000.0, down 91.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $63000.0 (down 95.05% YoY), and the FY2025 annual result was $63000.0, down 95.05% from the prior year.
• Other financing activities slipped to $63000.0 in Q1 2025 per AKBA's latest filing, from $522000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $44.8 million in Q1 2021 and troughed at $63000.0 in Q1 2025.
• A 4-year average of $17.2 million and a median of $750000.0 in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2025: Other financing activities declined 10.68% in 2022, then tumbled 91.6% in 2025.
• A 4-year view of Other financing activities shows it stood at $44.8 million in 2021, then decreased by 10.68% to $40.0 million in 2022, then slumped by 98.7% to $522000.0 in 2024, then plunged by 87.93% to $63000.0 in 2025.
• Business Quant data shows AKBA's Other financing activities at $63000.0 in Q1 2025, $522000.0 in Q3 2024, and $750000.0 in Q1 2024.